Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Portugal launches COPD detection programme

This article was originally published in Clinica

Executive Summary

Portugal has begun to roll out a national chronic obstructive pulmonary disorder (COPD) early detection programme. The initiative features the provision of spirometry and other diagnostic equipment in mobile units that are designed to complement local primary care provision. The aim of the programme is to improve early detection rates and improve care outcomes; until now, COPD diagnosis has only been offered through hospital referral. The condition affects more than 5% of the Portuguese population, according to the health ministry. The programme was launched in Portugal's northern region; it is scheduled to be extended across the Lisbon North area by the end of this month.

You may also be interested in...



Novartis Q4 Preview: Launches Likely To Deliver

Having had a very fruitful year in terms of regulatory approvals, the Swiss major will reveal how successful its new products have been commercially. Of particular interest will be the performance of eye drug Beovu as it takes on Bayer's rival Eylea.

Executives On The Move: New Picks For Finance Posts At Cambrex And Editas Medicine, And Zimmer Biomet Fills Communications Spot

Gene-editing company Editas Medicine appoints a new CFO, while Affimed and NexImmune bring new chief medical officers on board.

Big Win For EMA On Transparency

The European Court of Justice has confirmed the European Medicines Agency’s approach to disclosure of data submitted as part of a marketing authorization application. It is a big disappointment for industry, which nonetheless says it supports responsible data sharing and will support efforts to develop a balanced approach.

Topics

UsernamePublicRestriction

Register

MT043501

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel